Outcomes of female reproductive performance with assisted reproductive techniques after recent mild to moderate COVID-19 infections: An observational study DOI Open Access
Ashraf Moini,

Narges Najafpour,

Ladan Kashani

et al.

Daehan saengsik uihak hoeji/Clinical and experimental reproductive medicine, Journal Year: 2024, Volume and Issue: 51(3), P. 268 - 275

Published: March 25, 2024

The purpose of this study was to evaluate the impact preimplantation genetic testing for aneuploidy (PGT-A) on clinical outcomes among high-risk patients. This retrospective involved 1,368 patients and same number cycles, including 520 cycles with PGT-A 848 without PGT-A. participants comprised women advanced maternal age (AMA) those affected by recurrent implantation failure (RIF), pregnancy loss (RPL), or severe male factor infertility (SMF). associated significant improvements in rate (IR) ongoing rate/live birth (OPR/LBR) per embryo transfer cycle AMA (39.3% vs. 16.2% [p<0.001] 42.0% 21.8% [p<0.001], respectively), RIF (41.7% 22.0% 47.0% 28.6% RPL (45.6% 19.5% 49.1% 24.2% respectively) groups, as well IR SMF group (43.3% 26.5%, p=0.011). Additionally, lower overall incidence rates (16.7% 34.3%, p=0.001) 50.0%, p<0.001) groups. However, OPR/LBR total across all groups did not significantly exceed that control demonstrated beneficial effects our findings indicate these benefits are more pronounced carefully selected candidates than entire patient population.

Language: Английский

Immune Cells, Gut Microbiota, and Vaccines: A Gender Perspective DOI Creative Commons
Pierluigi Rio, Mario Caldarelli,

Monica Chiantore

et al.

Cells, Journal Year: 2024, Volume and Issue: 13(6), P. 526 - 526

Published: March 17, 2024

The development of preventive and therapeutic vaccines has played a crucial role in preventing infections treating chronic non-communicable diseases, respectively. For long time, the influence sex differences on modifying health disease not been addressed clinical preclinical studies. interaction genetic, epigenetic, hormonal factors plays sex-related epidemiology manifestations, response to treatment. Moreover, is one leading influencing gut microbiota composition, which could further explain different predisposition diseases men women. In same way, between sexes occur also immune vaccines. This narrative review aims highlight these differences, focusing Comparative data about responses, vaccine effectiveness, side effects are reviewed. Hence, intricate interplay sex, immunity, will be discussed for its potential vaccination. Embracing sex-oriented perspective research may improve efficacy allow design tailored schedules.

Language: Английский

Citations

11
Menstrual disorders following COVID-19 vaccination: a review using a systematic search DOI Creative Commons

Veerle R. Smaardijk,

Rana Jajou, A. Kant

et al.

Frontiers in Drug Safety and Regulation, Journal Year: 2024, Volume and Issue: 4

Published: Jan. 31, 2024

Introduction: Menstrual disorders are commonly reported after COVID-19 vaccination and heavy menstrual bleeding was added to the product information of vaccines Moderna Pfizer. The aim this review, using a systematic search, is provide an overview available literature on risk vaccination. Methods: review conducted according Preferred Reporting Items for Systematic reviews Meta-Analysis (PRISMA) guidelines. A PubMed search performed 15 August 2023, including solely quantitative studies in English Dutch. Results: total 61 were included, which 40 cross-sectional studies, 18 cohort three self-controlled case series. Outcomes included wide variety disorders, changes cycle length ( n = 54), amount 44), menses 30), experience (pre)menstrual pain 21), breakthrough 18). All found higher percentage at least one disorder first different types doses. Discussion: In conclusion, evidence suggests that may cause women reproductive age. However, there need more longitudinal because important limitations study designs many studies. Although short-lived predominantly mild, it healthcare professionals be informed about these potential adverse reactions assess events clinical trials vaccines.

Language: Английский

Citations

6
Artificial intelligence models predicting abnormal uterine bleeding after COVID-19 vaccination DOI Creative Commons

Yunjeong Choi,

Jaeyu Park, Hye Jun Kim

et al.

Scientific Reports, Journal Year: 2025, Volume and Issue: 15(1)

Published: Feb. 27, 2025

Language: Английский

Citations

0
Association between COVID-19 and Irregular Menstruation and Abnormal Uterine Bleeding: A Two-Sample Mendelian Randomized Analysis DOI

紫程 崔

Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(03), P. 2357 - 2368

Published: Jan. 1, 2025

Language: Английский

Citations

0
Abnormal uterine bleeding and associated factors: a cross-sectional study in high-performance Peruvian athletes DOI Creative Commons

Ivanna Querevalú-Pancorbo,

Luis F Rojas-Cama,

Fernando Soncco-Llulluy

et al.

BMJ Open Sport & Exercise Medicine, Journal Year: 2024, Volume and Issue: 10(2), P. e001820 - e001820

Published: May 1, 2024

Abnormal uterine bleeding (AUB) is a problem that affects women and can cause outcomes such as anaemia, affecting women's quality of life. In high-performance athletes, this be further exacerbated by intense physical activity, strict nutritional regimens stress.

Language: Английский

Citations

2
Outcomes of female reproductive performance with assisted reproductive techniques after recent mild to moderate COVID-19 infections: An observational study DOI Open Access
Ashraf Moini,

Narges Najafpour,

Ladan Kashani

et al.

Daehan saengsik uihak hoeji/Clinical and experimental reproductive medicine, Journal Year: 2024, Volume and Issue: 51(3), P. 268 - 275

Published: March 25, 2024

The purpose of this study was to evaluate the impact preimplantation genetic testing for aneuploidy (PGT-A) on clinical outcomes among high-risk patients. This retrospective involved 1,368 patients and same number cycles, including 520 cycles with PGT-A 848 without PGT-A. participants comprised women advanced maternal age (AMA) those affected by recurrent implantation failure (RIF), pregnancy loss (RPL), or severe male factor infertility (SMF). associated significant improvements in rate (IR) ongoing rate/live birth (OPR/LBR) per embryo transfer cycle AMA (39.3% vs. 16.2% [p<0.001] 42.0% 21.8% [p<0.001], respectively), RIF (41.7% 22.0% 47.0% 28.6% RPL (45.6% 19.5% 49.1% 24.2% respectively) groups, as well IR SMF group (43.3% 26.5%, p=0.011). Additionally, lower overall incidence rates (16.7% 34.3%, p=0.001) 50.0%, p<0.001) groups. However, OPR/LBR total across all groups did not significantly exceed that control demonstrated beneficial effects our findings indicate these benefits are more pronounced carefully selected candidates than entire patient population.

Language: Английский

Citations

0